People In Health Care
Professor Rosemary Harrup, Tasmania
Rosemary Harrup trained in Victoria and Tasmania in Medical Oncology and Clinical Haematology, completing a dual Fellowship in 2001. She is the current Director of Cancer and Blood Services at the Royal Hobart Hospital (RHH), a role she has held since 2009.
External to the RHH she is a member of the board of the Cancer Council of Tasmania, the Tasmanian Cancer Registry Advisory Group and the RHH Research Foundation Scientific and Advisory Committee.
Rosemary is currently Deputy Chair of the Cooperative Trials Group for Neuro oncology (COGNO), a member of the Australian Brain Cancer Mission Steering Committee and the Australian Cancer Plan Tasmanian jurisdictional representative. She has a strong interest in clinical research, particularly in the areas of Clinical Trials in Brain Cancer, Malignant Haematology and Late Effects and is an active mentor for early career researchers.
Australian Health Journal spoke to Rosemary about her journey in medicine and specifically her work in Clinical Trials in Brain Cancer and the value she placed on her senior clinicians as mentors and how she now mentors others.
-
Smart technology in wound care
Throughout her journey around wound care, Santosh Kaur was frustrated to see the simple gaps in wound care resulting in negative patient outcomes. Santosh is the founder of SmartHeal which launched in 2020.
SmartHeal replaces the nurses taking cumbersome manual measurements and manual sharing of important wound data with a no touch technique. It aims for healthcare professionals to have live remote access to wound data, make wound assessments and assist with speech to text notes thus saving time, cost and people. SmartHeal also aims to assist healthcare professionals in providing optimum wound care by analysing the wound tissue for infection, moisture and providing suggestions for suitable dressing.
-
New bar for cosmetic plastic surgeon accreditation
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
-
Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
